Office of Translational Alliances and Coordination



Beyond the Science: Entrepreneurial Support and Commercialization Resources

Stephanie Davis, PhD and Kathleen Rousche, PhD

Catalyze Webinar

4/25/22



NHLBI Mission

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a *research, training, and education* program to promote the *prevention* and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

NHLBI's Strategic Goals:

Understand Human Biology

Reduce Human Disease Develop
Workforce &
Resources

Advance Translational Research



OTAC Mission

Improve probability of NHLBI-funded technologies impacting patients

Lead training and educational programs for HLBS innovators

Goals

Broaden diversity, inclusion, and reach of the small business program

Create novel solutions to meet unmet HLBS needs

MISSION

To accelerate the translation of discoveries and innovations into new biomedical products and services for heart, lung, blood and sleep diseases and disorders

VISION

Development of a biomedical community that rapidly commercializes heart, lung, blood, and sleep technologies to improve public health



NHLBI Innovation and Commercialization Office Programs/Services

Academic Innovation Small Business Innovation Innovator Support Proof of Concept/Point of Care Programs SBIR/STTR and associated programs Unique expert staff Commercialization **CAPCaT** Catalyze **Advisory Services Programs** (academic & small biz) (academic & small biz) Awards to **Partnering Diversity** NCAI/REACH **Accelerate Opportunities & Programs** (academic) **Pitch Coaching** Commercialization **NHLBI Mentor Network** Small **Business** Community **Both**

Academic Community

Advisory Experts at NHLBI



Renée Arnold, PharmD

Entrepreneur-In-Residence

Health Economics

Specialist



Gautam Prakash, PhD, JD Intellectual Property Advisor



Steve Flaim,
PhD, MBA
Investor-In-Residence



Kwame Ulmer, MBA Entrepreneur-In-Residence Regulatory Specialist



Kimberly Martin, PhD
Entrepreneur-In-Residence
Clinical Trial Specialist



Small Business Grant Programs

Small Business Innovation Research (SBIR)

Set-aside program for small business concerns to engage in federal R&D -- with potential for commercialization

Federal agencies with an extramural R&D budget > \$100M

Small Business Technology Transfer Research (STTR)

Set-aside program to facilitate cooperative R&D between small business concerns and US research institutions -- with potential for commercialization

Federal agencies with an extramural R&D budget > \$1B

SET ASIDE




(FY21)



(FY21)



NIH SBIR/STTR Budget Allocations FY2021



SBIR \$1B STTR \$146M Total \$1.23 B

NHLBI: ~\$120M



SBIR/STTR Program Eligibility

√

Organized for-profit U.S. business




500 or fewer employees, including affiliates



Work must be done in the U.S. (with few exceptions)




> 50% U.S.- owned by individuals and independently operated **OR**



OR (SBIR ONLY)


> 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these





Electronic Submission

SBIR/STTR grant applications and SBIR contract proposals must be submitted electronically.



REQUIRED REGISTRATIONS


- DUNS Number (Company)
- System for Award Management (SAM)
- Grants.gov (Company)
- eRA Commons (Company and all PD/PIs)
- SBA Company Registry at SBIR.gov

- Grants submit via ASSIST or Grants.gov Workspace
- For contracts, submit proposals with <u>electronic</u>
 <u>Contract Proposal</u>
 <u>Submission</u> (eCPS)
 website



Why Seek SBIR/STTR Funding

- Provides seed funding for innovative technology development
- One of the largest funding sources of early stage life sciences in the US
- No repayment required; Not a loan = non-dilutive capital
- IP rights are normally retained by the small business
- Provides recognition, verification, and visibility
- Can provide leverage to attract other funding and collaboration (e.g., venture capital, strategic partner)






SBIR vs. STTR Programs

	SBIR	STTR
Partnering	Permits partnering	Requires a non-profit research institution partner
Principal Investigator	Primary employment (>50%) must be with the small business	PI may be employed by either the research institution partner or small business and devote at least 10% effort to the project
Work Requirement	Guidelines: May outsource up to 33% (Phase I), 50% (Phase II)	Minimum Work Requirements: 40% Small Business 30% Research Institution Partner




Phased Program





Timeline: Application to Award





NHLBI Application Cycles


Due Dates	Review meetings	Advisory Council Round	Earliest Project Start Date
January 5	March	May	July
April 5	June	October	December
September 5	November	January	April



The NHLBI Small Business Program

Innovative and commercially-promising products to prevent, treat and diagnose heart, lung, blood, and sleep (HLBS)-related diseases

Technologies Funded by NHLBI SBIR/STTR Program



~\$120M

Approximate annual non-dilutive funds

~312

Active projects



NHLBI Mission Space



Heart

- Arrhythmias
- Atherothrombosis
- Chronic Heart Failure
- Congenital Heart Defects
- Coronary Artery Disease
- Hypertension

Lung

- •Acute Respiratory Distress Syndrome
- Asthma
- •Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Fibrotic Lung Disease
- Pulmonary Hypertension





Blood

- Bleeding Disorders
- Anemia
- Myeloproliferative Disorders
- Sickle Cell Disease
- Thrombotic Disorders

Sleep

- Circadian Disorders
- Insomnia
- Obstructive Sleep Apnea
- Sleep-Disordered Breathing





NHLBI Budget Specifics

	Phase I	Phase II
Guidelines	\$150K/6-12 months	\$1M/2 years
Hard Cap	\$275K/6-12 months	\$1.83M/2 years
NHLBI Waiver Topics	\$>275K/6-12 months	\$>1.83M/2 years

NIH Topics for Budget Waivers

SBIR Budgets are defined by **total cost** and subcontracting is limited. Know the rules and the criteria.

Check Budget allowance in each FOA

Can request a 7% Fee

- Company Profit
- Of total budget

Fee for Service (* *Can Vary by IC*): CRO-type activities can count as small business costs providing that:

- 1. It is a commercially available service
- 2. All analysis is done by small business
- Fee per basis (no indirect costs by fee for service providers)



Technical and Business Assistance (TABA)

Discovery Phase I



Feasibility



\$6.5K for Technical and Business
Assistance-related expenses
(Request during application or through NOT-OD-21-062)

NIHAdministered
TABA Needs
Assessment
Program

Development
Phase II



Full R/D



\$50K for Technical and Business Assistance-related expenses (Request during application) NIHAdministered
TABA
Consulting
Services

Examples of activities supported by TABA Funds

Assistance with product sales

Intellectual property protections

Market research and/or validation

Development of regulatory plans

Development of manufacturing plans

Access to technical and business databases



Omnibus Funding Opportunity Announcements

PA-21-259

R43/R44 Clinical Trial Not Allowed PA-21-260

R43/R44 Clinical Trial Required

PA-21-261

R41/R42 Clinical Trial Required

PA-21-262

R41/R42 Clinical Trial Not Allowed



Targeted SBIR/STTR FOAs



Innovations for Healthy Living SBIR RFA (MD-22-004)

• Funds the development of devices, diagnostic tools, and other technologies specifically designed for use in patients with HLBS conditions from NIH-designated Health Disparity Populations

Next Due Date: TBA



HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management SBIR/STTR RFAs (NS-20-008, NS-20-009, NS-20-010, NS-20-011)

• Funds the development of technologies and non-addictive therapeutics that may improve pain management in patients with HLBS conditions as well as technologies and therapeutics to minimize HLBS complications of analgesic use

Next Due Date: September 6th, 2022



Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health (NOT-EB-21-001)

• Funds the development of tools, technologies, and devices for the diagnosis of pregnancy-related HLBS conditions

Standard Due Dates

Late-Stage Support for NHLBI Grantees

Max. two

submissions per

parent grant

Supports late-

stage R&D activities

Commercialization Readiness Pilot Program (PAR-20-128, PAR-20-129, PAR-20-130)

Phase IIB Bridge and Small Market RFAs (RFA-HL-23-009 and RFA-HL-23-008)

Up to \$500K over two years

SB1 mechanism

Virtually no subcontracting restrictions

TABA not allowed

Follow standard due dates

May be active concurrently with Phase II/IIB parent grant

Technology does not require regulatory clearance

No matching funds necessary

Up to \$3M over three years

R44 mechanism

Adheres to SBIR subcontracting restrictions

Up to \$50K in TABA funds allowed

One receipt date per year

May only start after Phase II parent grant ends

Technology requires regulatory clearance

Matching funds strongly encouraged



Innovation Corps (I-Corps) at NIH™ (PAR-22-073)

- Launched at the NIH in 2014 as a program based on the Lean Startup Methodologies
- Promotes customer discovery experience by requiring participants to conduct ~100 interviews over eight weeks
 - Content from interviews helps refine proposed business model
 - "You cannot commercialize something that nobody wants
- Open to current Phase I and early stage Fast-Track SBIR/STTR awardees
- Two receipt dates per year
 - Next due date November 15th, 2022
- Selected companies may receive up to \$55K for course registration and travel expenses





Concept to Clinic: Commercializing Innovation Program (C3i)

 The NIBIB C3i program provides medical device innovators with the tools and frameworks that are required to commercialize their technologies

Validation/Execution


- Twenty-four (24) weeks of entrepreneurial training
- Open to SBIR/STTR and non-SBIR/STTR grantees
- Due date August 5th, 2022





Administrative Supplements to Promote Diversity (PA-21-345)

- Provides financial support for SBIR/STTR awardees to hire early-career scientists to enhance the diversity of the NIH-supported workforce
- Allows candidate to receive
 - Entrepreneurial training
 - Scientific training
 - Real-world experience
- Covers the following expenses
 - Salary Support
 - Travel
 - Supplies
- Eligibility Criteria
 - Must have an active SBIR/STTR award
 - Candidate <u>must</u> be a U.S. Citizen or a permanent resident



Partnering Opportunities & Pitch Coaching

- Connects NHLBI-funded companies to potential investors and strategic partners
- Pitch Coaching from office advisory team
- Free registration



- 1. American Heart Association (AHA) Conference, Nov 2020
- 2. Redefining Early-Stage Investments (RESI), Jan 2021
- 3. Biotech SEED Showcase, Jan 2021
- 4. Redefining Early-Stage Investments (RESI), Mar 2021
- American College of Cardiology (ACC) Innovation Showcase, Apr 2021
- 6. Angel Capital Association (ACA) Annual Meeting, May 2021
- BIO Annual Meeting Digital, June 2021
- 8. CaPCAT Showcase, Jun 2021
- 9. Digital Redefining Early-Stage Investments (RESI), Sep 2021
- 10. BioPharm America Digital, Sep 2021
- 11. NIH Innovation Conference (NIC)(SEED/OER)
- 12. Life Science's Summit (LSS), Nov 2021

NIH Applicant Assistance Program (AAP)

- FREE ten-week coaching program for new and previously-unsuccessful Phase I SBIR/STTR grant applications
- Participating ICs: NHLBI, NCI, NINDS, NIA, NCCIH, NIEHS, NCATS, NINR, NIAAA, NICHD

NIH AAP	NOT PROVIDED	
Phase I Preparation Support/Review	Grant Writer	
Review of Specific Aims Page	Development of Research Plan	
Submission Process Coaching	Completion of submission or registration processes for you	

Goal of the AAP

Provide a mentor for applicants with great technology but little NIH experience and limited NIH experience in their network, including businesses owned and led by women and/or historically underrepresented individuals

For more information, visit the **AAP Webpage**

Next Due Date: May 23rd, 2022



Catalyze Program

Enhancing Support for Translational Research

Catalyze provides a comprehensive suite of support and services to academic investigators and small businesses to facilitate the translation of basic heart, lung, blood and sleep discoveries into viable therapeutics, devices and diagnostics ready for human testing.

Funding

Unique funding strategy to leverage federal investment with matching commitments and flexibility to adjust to technical challenges

Individualized Support

Milestone-driven project management and technical support to mitigate technical risk

Coordinated Approach

Seamless continuum of funding programs to advance promising heart, lung, blood and sleep technologies from validation through first-in-human trials

Program Flexibility


Evaluation and oversight to adjust program and projects based on trends, challenges, and to share best practices



For more information email MILBI_Catalyze@mail.nih.gov



Activities Supported by Catalyze



Visit the **Catalyze Website** for more information



Catalyze Program Funding Opportunities

Next Application Deadline: July 21st, 2022

Devices

- Protype Design and Testing, Diagnostic Disease Target Identification, Assay Development and Research Tool Dev. (RFA-HL-23-013)
- Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development, and Design Characterization, and Research Tool Testing and Validation (RFA-HL-23-014)

Small Molecules and Biologics

- Target Identification and Validation, Preliminary Product/Lead Series Identification (<u>RFA-HL-23-011</u>)
- Preliminary Product/Lead Series Identification (<u>RFA-HL-23-012</u>)

US-based academic, non-profit institutions, and US-owned small businesses are eligible to apply

Enabling Technologies

 Enabling Technologies and Transformative Platforms for HLBS Research (<u>RFA-HL-23-010</u>)





NHLBI Small Biz Hangouts

You Tube

NHLBI Playlist

Regulatory

Navigating the FDA Website

- "First Contact" with FDA
- Finding the Right Regulatory Consultant
- Developing a Target Product Profile

Commercialization

- Writing your Phase II Commercialization Plan
- Identifying and Connecting With Your Customer
- How Pharma Evaluates New Therapeutic Opportunities

Intellectual Property

- Intellectual Property Basics for the New Innovator
- Making Your Mark: The Use and Care of Trademarks
- Patent Litigation: Basics, Defense, and Offense –
 Parts 1 & 2



Helpful Resources For Applicants

- 2021 HHS Small Business Conference Playlist
- Writing a Good Commercialization Plan
- Writing a Competitive Commercialization Plan (NIA)
- Sample Applications
 - NIAID SBIR/STTR Grant Applications
 - NIA Sample SBIR Grant Applications
 - NCI Sample SBIR/STTR Grant Applications
- SF424 SBIR/STTR Application Instructions
- Annotated Form Set for NIH SBIR Grant Applications
- SBIR/STTR Application Process Infographic
- SBIR/STTR Study Section List
- CSR Assisted Referral Tool
- NIH RePORTER
 - Database of NIH-supported Research
 - Matchmaker: find similar projects or program officials





Connect with Us!

Connect with the NIH

LISTSERV: Email
 LISTSERV@LIST.NIH.GOV with
 the following text in the message body: subscribe SBIR-STTR your name

• Email: sbir@od.nih.gov

Connect with the NHLBI

NHLBI Small Business Inquiry

° 💟 @NHLBI_SBIR

- Sign up for our NHLBI Newsletter HERE
- Email: NHLBI SBIR@mail.nih.gov



Thank you!

